Validating biomarkers for effective drug development

Triptorelin is indicated for palliative treatment of advanced prostate cancer.

It decreases LH and FSH secretion when administered long-term and thus decreases testosterone and estrogen levels."This quarter's progress, with key hires to the executive team and advancements in the clinic, has reinforced Merrimack's refined corporate and clinical s... 2, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. Needham will help design and implement Merrimack's strategy for its broad pi...(Nasdaq: MACK) today announced that the company will host its second quarter 2017 investor conference call and webcast at am ET on Wednesday, August 9, 2017. CAMBRIDGE, Mass., June 19, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.Leuprolide is indicated as palliative treatment for advanced prostate cancer when orchiectomy or estrogen administration is not indicated or is unacceptable to the patient.It is a potent inhibitor of gonadotropin secretion when given continuously in therapeutic doses.Gn RH agonists bind to the Gn RH receptors on pituitary gonadotropin-producing cells, causing an initial release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) and consequently a rise in testosterone levels for a few weeks.


Leave a Reply